Turning in MFB-lesioned rats and antagonism of neuroleptic-induced catalepsy after lisuride and LSD.
D015116:5,7-Dihydroxytryptamine; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology*; D001522:Behavior, Animal / Q000502:physiology; D001930:Brain Injuries / Q000139:chemically induced; D002375:Catalepsy / Q000139:chemically induced*; D004873:Ergolines / Q000494:pharmacology*; D005260:Female; D006220:Haloperidol; D006801:Humans; D006892:Hydroxydopamines; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology*; D008297:Male; D008474:Medial Forebrain Bundle / Q000187:drug effects / Q000503:physiopathology*; D009434:Neural Pathways / Q000503:physiopathology*; D011346:Prochlorperazine; D051381:Rats; D012399:Rotation; D014508:Urea / Q000031:analogs & derivatives / Q000494:pharmacology
D004873:Ergolines; D006892:Hydroxydopamines; D015116:5,7-Dihydroxytryptamine; D008238:Lysergic Acid Diethylamide; D014508:Urea; D006220:Haloperidol; D001058:Apomorphine; D011346:Prochlorperazine